Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States

RegulatoryapprovedC-1101Positive

AI Analysis

Summary

Consano Bio received FDA IND clearance to expand the clinical development of C-1101, a potential first-in-class, disease-modifying non-opioid therapy for chronic sciatica, into the United States.

Clinical Trial Data

Outcome Details

FDA Investigational New Drug (IND) clearance received to expand C-1101 clinical development program into the United States

Importance:6/10

Sentiment:

0.80

IND clearancefirst-in-classnon-opioiddisease-modifyingchronic pain

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on July 20, 2026 12:10 PM

Read Original